Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/12/2018 01/15/2018 01/16/2018 01/17/2018 01/18/2018 Date
3581(c) 3536(c) 3575(c) 3500(c) 3437 Last
4 752 515 3 352 065 4 188 157 4 636 448 1 449 499 Volume
-1.82% -1.26% +1.10% -2.10% -1.80% Change
More quotes
Financials ($)
Sales 2017 14 939 M
EBIT 2017 5 735 M
Net income 2017 2 567 M
Debt 2017 19 263 M
Yield 2017 0,74%
Sales 2018 15 479 M
EBIT 2018 6 126 M
Net income 2018 3 281 M
Debt 2018 15 426 M
Yield 2018 0,81%
P/E ratio 2017 19,44
P/E ratio 2018 12,68
EV / Sales2017 4,24x
EV / Sales2018 3,84x
Capitalization 44 022 M
More Financials
Company
Shire Plc is a biopharmaceutical company.The company focuses on developing and marketing innovative medicines for patients with rare diseases and other conditions.It engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines... 
Sector
Pharmaceuticals
Calendar
02/15Earnings Release
More about the company
Surperformance© ratings of Shire
Trading Rating : Investor Rating :
More Ratings
Latest news on SHIRE
01/16 SHIRE : Megan Sullivan Joins LTEN Board of Directors
01/16 SHIRE : granted EU marketing authorization for ADYNOVI for adults and adolescent..
01/15 SHIRE : 70+ Year Commitment to the Hemophilia Community
01/15 SHIRE : granted EU marketing authorization for ADYNOVI®▼ for adults and..
01/15 SHIRE : granted EU marketing authorization for ADYNOVI®▼ for adults and ad..
01/10 SHIRE : 65-- Carbamazepine
01/09 SHIRE : Xiidra* Approved by Health Canada To Treat the Signs and Symptoms of Dry..
01/09 SHIRE : Kamada Announces Interim Results from Phase 2 Clinical Trial of Intraven..
01/08 SHIRE : cuts 2020 revenue target, prepares for spin-off of ADHD drugs
01/08 Weak results weigh on FTSE 100, profit warning pummels Mothercare
More news
Sector news : Pharmaceuticals - NEC
01/17 TSX ends up as banks lead rally after rate hike
01/17 ASPEN PHARMACARE : Drugmaker GSK cuts back in Africa to hone emerging markets mo..
01/17 EXCLUSIVE : J&J attracts Chinese interest for diabetes business in potential $3-..
01/17 Allergan Pact Advances -- WSJ
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on SHIRE 
SHIRE - 2015
Sellers pressure likely to dominate
SELL
SHIRE - 2014
Benefit from the resuming bullish trend
BUY
More Strategies
Latest Tweets
09:05aHear from Merck and Shire as they debate the effect of parallel trade on phar.. 
07:22a#Mareeba Shire Council speaks out over multiple dog attacks  
05:59aUpper Hunter Shire Council : ESCAPE THE HEAT AT UPPER HUNTER SHIRE POOLS THIS.. 
01/17Trio jailed for horrendous chemical attack outside McDonald's in . shire
2
01/16$SHPG: Shire plc granted EU marketing authorization for ADYNOVI  
More tweets
Qtime:122
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Shire's hemophilia A med Adynovi OK'd in Europe
01/12 A Warning Sign Of High Dividend Growth Stocks
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 67,2 $
Spread / Average Target 39%
EPS Revisions
Managers
NameTitle
Dominic Blakemore CEO & Independent Non-Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
John Miller Chief Financial Officer
Howard Mayer Senior VP & Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-10.26%44 848
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287